ClinicalTrials.gg
Not yet recruitingNCT07177716Updated Sep 17, 2025

Efficacy and Safety of LB1410 Plus Lenvatinib With or Without LB4330 in Advanced Recurrent/Metastatic Cervical Cancer

A Phase 2/3 interventional study of LB1410 and LB4330 in Cervical Cancer, sponsored by L & L Bio Co., Ltd., Ningbo, China. Not yet recruiting at 1 site in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-17.

Sponsored by L & L Bio Co., Ltd., Ningbo, China · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
120
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 456 studies in Uterine Cervical Neoplasms with a site in China — 206 open to participants now, 241 under way, 35 of them phase 3. Uterine Cervical Neoplasms · China.

Planned enrollment
141st of 361
120 · median 90
Started
2025
with 44 others
Phase 2/3
11 of 456
6 open now
Primary completion
2028-12
later than 221 of 240 live
Registered
419th of 456
by date

Among the 456 studies in Uterine Cervical Neoplasms with a site in China, this one is the 141st largest by planned enrollment of the 361 interventional ones that give a count, is one of 45 that started in 2025, is one of 11 in phase 2/3, reaches primary completion later than 221 of the 240 other live ones, and was the 419th registered.

Uterine Cervical Neoplasms

2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 680 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

206 of the 456 studies in Uterine Cervical Neoplasms with a site in China are open now. Recruiting first, the newest first:

201 more — sign in →

All 206 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 456 studies in Uterine Cervical Neoplasms with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, randomized, open-label Phase II/III clinical study, aiming to evaluate the efficacy and safety of LB1410 in combination with lenvatinib (whether in combination with LB4330)versus the chemotherapy regimen selected by the investigators for patients with advanced recurrent/metastatic cervical cancer.

Read the detailed description

This study is an open-label, multicenter Phase II/III clinical trial in advanced/metastatic cervical cancer to evaluate the antitumor efficacy, safety, tolerability, pharmacokinetics (PK), and biomarkers of LB1410 in combination with lenvatinib, with or without LB4330.

03

Conditions studied

  • Cervical Cancer

Keywords

  • cervical carcinoma
  • LB1410
  • LB4330
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed cervical squamous cell carcinoma, adenosquamous carcinoma, or HPV-associated cervical adenocarcinoma.
  2. Recurrent or cervical cancer with disease progression or intolerable toxicity after standard therapy, with no more than three in the recurrent or metastatic setting, with only one prior line of therapy containing /anti-PD-L1 agents.
  3. At least one per v1.1 at screening period.
  4. Age ≥18 years.
  5. (ECOG) performance status of 0 or 1.
  6. Investigator-assessed ≥12 weeks.
  7. Adequate hematological function, liver function, renal function and coagulation function.
  8. Adequately controlled blood pressure (BP) with or without antihypertensive medication.
  9. Any related toxicity or prior adverse events (AEs) had recovered to baseline or ≤Grade 1 per v5.0.
  10. Women of must agree to use effective from the time of signing the form, throughout the study, and for 6 months after the last dose of study treatment.
  11. The patient is capable of understanding and voluntarily signing the informed consent form.

Exclusion criteria

Exclusion Criteria

  1. For cohorts containing lenvatinib, patients meeting any of the following criteria are ineligible:

    1. Radiographic (CT or MRI) evidence of tumor invasion around major blood vessels, or investigator judgment that the tumor is highly likely to invade major blood vessels during the study, leading to life-threatening hemorrhage;
    2. History of bleeding, coagulation disorders, or current use of warfarin, aspirin, or other antiplatelet agents;
    3. Urine protein ≥2+ and 24-hour urine protein quantification ≥1.0 g;
    4. Factors affecting oral drug absorption;
    5. Intestinal or existing ≥Grade 3 gastrointestinal or non-gastrointestinal fistulas;
    6. History of hypertensive crisis or hypertensive encephalopathy.
  2. Pregnant or breastfeeding women.
  3. History of ≥Grade 3 immune-related adverse events (irAEs) during prior immunotherapy.
  4. Active disease or symptomatic autoimmune disease.
  5. Any of the following prior treatments:

    1. Live or attenuated within 4 weeks before the first dose;
    2. Immunomodulatory drugs (e.g., thymosin, interleukin-2, interferon) within 14 days before the first dose;
    3. History of allogeneic organ transplantation, peripheral hematopoietic stem cell transplantation, or bone marrow transplantation.
  6. Positive test, active syphilis, active virus (HBV) infection, or active virus (HCV) infection.
  7. Other within the past 3 year.
  8. , spinal cord compression, symptomatic or unstable .
  9. Uncontrolled or poorly controlled diabetes.
  10. Arterial/venous thrombotic events within 6 months.
  11. and unstable pleural, peritoneal, or pericardial effusion.
  12. Known interstitial lung disease.
  13. Prior use of drugs with the same mechanism as this study (e.g., antibody combined with TIM-3 antibody, PD-1/TIM-3 bispecific antibodies).
  14. Any other condition (including severe medical or psychiatric illness) or clinically significant laboratory abnormality that may affect patient safety or study integrity per investigator judgment.
  15. (Applicable only to containing-LB4330 cohorts): History of Grade IV thrombocytopenia (per ) from any prior anti-cancer regimen within the past 2 years, or prior exposure to any interleukin-10 (IL-10) based agent.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Cohort 1: LB1410 + Lenvatinib

    LB1410 (intravenous, Q2W) with lenvatinib (oral, QD),up to 2 years

    Biological: LB1410 · Drug: Lenvatinib

  • Experimental
    Cohort 2: LB1410 + LB4330 + Lenvatinib

    LB1410 (IV, Q2W for up to 2 years), LB4330 (IV, Q2W for 4 cycles), and lenvatinib (oral, once daily for up to 2 years)

    Biological: LB1410 · Biological: LB4330 · Drug: Lenvatinib

  • Experimental
    Cohort 3: LB1410

    LB1410 (IV, Q2W for up to 2 years)

    Biological: LB1410

  • Experimental
    Cohort 4: LB1410 + LB4330

    LB1410 (IV, Q2W for up to 2 years) plus LB4330 (IV, Q2W for 4 cycles)

    Biological: LB1410 · Biological: LB4330

Interventions

  • BiologicalLB1410

    LB1410 (IV, Q2W for up to 2 years)

  • BiologicalLB4330

    LB4330 (IV, Q2W for 4 cycles)

  • lenvatinib (oral, once daily for up to 2 years)

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) assessed by an Independent Radiology Review Committee (IRRC)

    defined as the percentage of patients with a best overall response of Complete Response or Partial Response per RECIST 1.1.

    Time frame: Approximately 24 months

  2. Duration of Response (DOR) assessed by an Independent Radiology Review Committee (IRRC)

    defined as the time from the first documented response (CR or PR) to the first documented disease progression or death due to underlying cancer per RECIST 1.1.

    Time frame: Approximately 24 months

Secondary outcomes

  1. Objective Response Rate (ORR) assessed by the investigator

    defined as the percentage of patients with a best overall response of Complete Response or Partial Response per RECIST 1.1.

    Time frame: Approximately 24 months

  2. Duration of Response (DOR) assessed by the investigator

    defined as the time from the first documented response (CR or PR) to the first documented disease progression or death due to underlying cancer per RECIST 1.1.

    Time frame: Approximately 24 months

  3. Disease Control Rate (DCR)

    defined as the percentage of evaluable patients achieving a best overall response of complete response (CR), partial response (PR), or stable disease (SD) per RECIST 1.1 assessed by both the investigator and an Independent Radiology Review Committee (IRRC).

    Time frame: Approximately 24 months

  4. Progression-Free Survival (PFS)

    defined as the time from the first dose to the first documented disease progression per RECIST 1.1 or death due to any cause (whichever occurred first) assessed by both the investigator and an IRRC.

    Time frame: Approximately 24 months

  5. Overall Survival (OS)

    Overall Survival is defined as the time from the date of first study treatment to the date of death from any cause or the date of censoring.

    Time frame: Until participant death/end of study,approximately 24 months

  6. Safety and tolerability (Adverse Event reported per NCI-CTCAE v5.0)

    Incidence of treatment-emergent adverse events (TEAEs) and treatment-related adverse events reported per NCI-CTCAE v5.0

    Time frame: From the first dose administration to 30 days after the last dose

  7. ADA Antibody Positivity Rate of LB1410

    ADA Antibody Positivity Rate of LB1410

    Time frame: From the first dose administration to 30 days after the last dose

  8. Pharmacokinetic (PK) parameters of LB1410-Maximum (peak) Plasma Concentration(Cmax)

    The highest concentration a drug reaches in the bloodstream after a single dose.

    Time frame: From the first dose administration to Cycle 16 Day 1 (each cycle is 28 days)

  9. Pharmacokinetic (PK) parameters of LB1410-Trough Concentration(Ctrough)

    The minimum drug concentration at steady state, measured just before the next dose is administered.

    Time frame: From the first dose administration to Cycle 16 Day 1 (each cycle is 28 days)

  10. Pharmacokinetic (PK) parameters of LB1410-Area Under the Curve at Steady State(AUCss)

    The total area under the plasma concentration-time curve over one dosing interval at steady state, representing total drug exposure.

    Time frame: From the first dose administration to Cycle 16 Day 1 (each cycle is 28 days)

Other outcomes

  1. Biomarker(TIM3)

    Correlation between TIM3 expression and clinical efficacy endpoints (ORR, DCR, PFS, OS) as assessed by the investigator according to RECIST 1.1 criteria.

    Time frame: Until end of study,approximately 24 months

  2. Biomarker(PD-L1)

    Correlation between PD-L1 expression and clinical efficacy endpoints (ORR, DCR, PFS, OS) as assessed by the investigator according to RECIST 1.1 criteria.

    Time frame: Until end of study,approximately 24 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2025; primary completion for Dec 2028, 38 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2025
First posted
Sep 17, 2025
StartEst.
Oct 2025
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2028
Last update
Sep 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07177716
Lead sponsor
L & L Bio Co., Ltd., Ningbo, China
Responsible party
Sponsor
First posted
Sep 17, 2025
Start date
Oct 2025 (estimated)
Primary completion
Dec 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Sep 17, 2025

Study contacts

Yan Luan, Doctor
Contact
luanyn2@lnlbio.com
86-21-54152522
Xiaohua Wu, Doctor
Contact
Xiaohua Wu, Doctor
principal investigator · Fudan University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-PD-1/Anti-TIM-3 Bispecific Antibody LB1410

Start the discussion